Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Epidemiological Disease Burden and Cost of Illness of Systemic Lupus Erythematosus (SLE) in the US

Speaker(s)

Chopra A1, Bhalani S2, Jabin F2, Gaur A3, Kukreja I4, Roy A5, Gupta A6, Brooks L7, Sulzicki M8, Verma V9, Pandey S10, Field S11, Krebs B12
1Optum Global Solutions, India, Gurugram, HR, India, 2Optum Global Solutions, UHG, New Delhi, India, 3Optum, Gurugram, HR, India, 4Optum Global Solutions, India, New Delhi, DL, India, 5Optum, Gurgaon, HR, India, 6Optum, Eden Prairie, MN, USA, 7Optum, Basking Ridge, NJ, USA, 8Optum, Trumbull, CT, USA, 9Optum Global Solutions, India, Gurgaon, HR, India, 10Optum Global Solutions, India, noida, gautam buddha nagar, UP, India, 11Optum, Dallas, TX, USA, 12Optum, Tucson, AZ, USA

Presentation Documents

OBJECTIVE: SLE is an autoimmune disease which is inflammatory and can cause tissue damage in multiple organs. Total 5 million people around the world is suffering from SLE and out of them 1.5 million are Americans. 90% of patients are female and generally disease occur between age of 15-44. As SLE has no cure and It is important to know burden of disease and cost of illness of disease to support other research and educational purposes. Aim of the study is to measure epidemiological disease burden and analyze cost of illness of SLE in the US. METHOD: The data of burden of disease were derived from the health statistics and claims data available from 2016-2020, using the prevalence data available on one of the largest US managed care organizations representing about 15% of commercially insured lives and 23% of Medicare Part D beneficiaries. We will analyze number of patients each year in claims and identify change in prevalence of disease. And from number of patients, a measurement would be conducted for cost of disease each year. Total Cost of disease measured by inclusion of medical cost and pharmacy cost. RESULT: Information regarding burden of disease and cost of illness recognized from Optum claims information base and we observed the absolute number of patients experiencing SLE from year 2016-2020. this study shows prevalence of 2.6 per 1000 population in 2020 and which is around 57,217 number of adults. Total cost of SLE found $354 million in 2020, which is expanded throughout the long term. Cost is not adjusted for inflation. CONCLUSION: The consequences of this cross-sectional study propose that SLE is a widespread disease which has unknown cause and not curable. This research can help to identify burden of disease and can support other research, policies, and health programs.

Code

EPH74

Topic

Economic Evaluation, Epidemiology & Public Health, Study Approaches

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

No Additional Disease & Conditions/Specialized Treatment Areas